GRISEOFULVIN

Post-LOE

grisofulvin

Cipla

ANDAORALSUSPENSION

Approved

Sep 2007

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

GRISEOFULVIN (grisofulvin) by Cipla. Approved for tubulin inhibiting agent [epc]. First approved in 2007.

Drug data last refreshed 21h ago

$0.0BPart D

Mechanism of Action

Pharmacologic Class:

Tubulin Inhibiting Agent

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (3)

NCT04318535Phase 1Completed

Bioequivalence (BE) Study of Test Griseofulvin 500 Milligram (mg) Tablets Versus Reference and Dose Proportionality Study of Test Griseofulvin 250 mg and 500 mg Tablets Under Fed Conditions

Started Jan 2020

36 enrolled

Antifungal Agents

NCT00117754Phase 3Completed

Terbinafine Compared to Griseofulvin in Children With Tinea Capitis

Started Jul 2004

720 enrolled

Tinea Capitis

NCT00117767Phase 3Completed

Terbinafine Compared to Griseofulvin in Children With Tinea Capitis

Started Jun 2004

720 enrolled

Tinea Capitis

Company

Worked on GRISEOFULVIN at Cipla? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.